Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells

Rocha, Moises; Otero, Luize; Padilha, Telma; Dobbin, Jane; Fernandez, C de Souza; Abdelhay, Eliana; Fernandez, Teresa de Souza

doi:10.1038/bcj.2011.45

Cited by 2 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imatinib has been used as a first line therapy for CML patients. Different patterns of response to imatinib treatment have been recognized, ranging from best-case scenarios of rapid and unwavering response to difficult situations of intolerance and resistance, with the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells [ 12 – 14 ]. The resistant cancer cells emerged in different kinds of tumors, and research groups are studying these molecular mechanisms, especially in cancer stem cells (CSC) because of their dual role, as a tumor-initiating cell and as a source of treatment resistance cells [ 15 – 18 ].…”

Section: Introductionmentioning

confidence: 99%

Human Induced Pluripotent Stem Cells from Basic Research to Potential Clinical Applications in Cancer

Fernandez

Mencalha

2013

BioMed Research International

View full text Add to dashboard Cite

The human induced pluripotent stem cells (hiPSCs) are derived from a direct reprogramming of human somatic cells to a pluripotent stage through ectopic expression of specific transcription factors. These cells have two important properties, which are the self-renewal capacity and the ability to differentiate into any cell type of the human body. So, the discovery of hiPSCs opens new opportunities in biomedical sciences, since these cells may be useful for understanding the mechanisms of diseases in the production of new diseases models, in drug development/drug toxicity tests, gene therapies, and cell replacement therapies. However, the hiPSCs technology has limitations including the potential for the development of genetic and epigenetic abnormalities leading to tumorigenicity. Nowadays, basic research in the hiPSCs field has made progress in the application of new strategies with the aim to enable an efficient production of high-quality of hiPSCs for safety and efficacy, necessary to the future application for clinical practice. In this review, we show the recent advances in hiPSCs' basic research and some potential clinical applications focusing on cancer. We also present the importance of the use of statistical methods to evaluate the possible validation for the hiPSCs for future therapeutic use toward personalized cell therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Human Induced Pluripotent Stem Cells from Basic Research to Potential Clinical Applications in Cancer

Fernandez

Mencalha

2013

BioMed Research International

View full text Add to dashboard Cite

show abstract

A Validated Liquid Chromatographic Method for the Estimation of Imatinib Mesylate in Dosage Forms: Application to Chemometrics based Robustness Testing and Greenness Assessment

Panda

Mohanty

Pulusu

et al. 2023

ajc

View full text Add to dashboard Cite

An eco-friendly liquid chromatography method was developed for determining imatinib mesylate in pharmaceuticals. During pre-development studies, Using a greener mobile phase and a combination of qualitative and semi-quantitative green metrics techniques, the environmental sustainability of the procedure was maintained. Methanol:water (pH maintained at 3.5 using orthophosphoric acid) at 75:25%, v/v flowing at 1 mL/min was the final mobile phase used on a C-18 column. The diode array detector detected imatinib at 262 nm. Method specificity, accuracy, precision, selectivity and system suitability were tested over a linear concentration range of 5-120 μg/mL of imatinib. The limit of detection and limit of quantitation values were 1.5 and 5.0 μg/mL, respectively. In addition, the factorial design showed the procedure to be reliable with minimum testing. Finally, the method recovered the maximum (> 99%) of the analyte from the dosage form. Overall, the present method is suitable for routine applications in quality control of dosage forms of imatinib.

show abstract

Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells

Cited by 2 publications

References 15 publications

Human Induced Pluripotent Stem Cells from Basic Research to Potential Clinical Applications in Cancer

Human Induced Pluripotent Stem Cells from Basic Research to Potential Clinical Applications in Cancer

A Validated Liquid Chromatographic Method for the Estimation of Imatinib Mesylate in Dosage Forms: Application to Chemometrics based Robustness Testing and Greenness Assessment

Contact Info

Product

Resources

About